Introduction {#Sec1}
============

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy and encompasses a variety of morphological/architectural variants, all of which are characterized by a distinctive nuclear appearance. In recent years, PTC has become an important paradigm of solid tumour molecular pathogenesis principally arising from intensive investigation prompted by the Chernobyl accident.

The discovery of ret rearrangements \[[@CR12], [@CR13], [@CR35]\] and their association with radiation \[[@CR42]\] was followed by the demonstration of the BRAF V600E mutation \[[@CR21], [@CR30]\] found more commonly associated with sporadic PTC in non-radiation exposed populations \[[@CR22], [@CR32]\]. In the past, our group and others have noted an association between classic morphology and the BRAF V600E mutation and between variant morphology and ret rearrangements particularly ret/PTC-3 \[[@CR11], [@CR39]\]. Similarly ret/PTC-3 appears to strongly correlate with the solid/follicular variant seen commonly in children exposed to the Chernobyl fallout \[[@CR42]\]. Nevertheless, the utility of these genetic lesions to diagnostic pathology and clinical practice has remained negligible.

Recently, gene expression microarray technology has been used to attempt to identify clinically relevant biomarkers of malignancy related to the thyroid \[[@CR2], [@CR6], [@CR9], [@CR10], [@CR20], [@CR28]\]. The discovery of such a biomarker or panel of biomarkers allied to the gold standard triage method of fine needle aspiration cytology (FNAC) would represent a significant advancement in the treatment of the solitary thyroid nodule.

An intriguing but commonly occurring variant of PTC is known as follicular variant (FVPTC). This lesion, which by definition retains the classic nuclear features of PTC, shows no evidence of the architectural papillae. FVPTC may be a controversial lesion due to interobserver variation in its pathological diagnosis \[[@CR25]\]. Further, the occurrence of follicular patterned lesions with poorly or incompletely developed nuclear features may occur, which are easily dismissed as benign thyroid nodules. This has led to the controversial designation "well-differentiated tumour of uncertain malignant potential" for tumours of this type \[[@CR45]\].

It is clear that this is a complex and contentious area, and that further work needs to be done to ascertain the underlying molecular biology of this particular variant. Recently, inroads into elucidation of molecular pathways underpinning PTC have been carried out using microarray studies. The overriding objective of these investigations was to identify clinically useful biomarkers. However, the majority of these studies have analysed PTC as though it were a homogenous singular entity without deference in a detailed manner to sub-variants and, in particular, the most common variant (FVPTC). The identification of specific biomarkers of FVPTC and a deeper understanding of its origins are clearly warranted.

The aim of this expression microarray study using a novel microarray platform was twofold: to identify markers that distinguish PTC from benign thyroid tissue and lesions and, secondly, to identify potential markers and further explore the molecular pathology of FVPTC.

Materials and methods {#Sec2}
=====================

Patients and tissue samples {#Sec3}
---------------------------

Tissue from 25 thyroid resections was collected prospectively from patients undergoing partial or total thyroidectomy for a variety of reasons at St. James's Hospital, Dublin. The study had approval of the local ethics committee and informed consent was obtained from each patient by the clinical team before surgery. Small samples (\<1 cm) were divided and immediately snap-frozen in liquid nitrogen for storage at −80°C until use. Histopathological examination of formalin-fixed paraffin-embedded sections was performed by two pathologists (SF and MT) for diagnostic categorisation. Classification of neoplastic tissue was made according to a recognised system \[[@CR24]\]. The cohort comprised 11 benign lesions or conditions including follicular adenoma, nodular goitre, normal thyroid tissue, and Graves's thyroiditis. The remaining 14 samples were diagnosed as PTC and comprised six classical morphology PTC and eight FVPTC (see Table [1](#Tab1){ref-type="table"}). Immediately before RNA extraction, frozen sections were cut and stained to confirm the presence of representative lesional tissue with morphology corresponding to that noted in the diagnostic formalin-fixed paraffin-embedded sections. Table 1Sample cohortIdentifierDiagnosisN1Normal thyroid tissueN2Normal thyroid tissueN3Lymphocytic thyroiditisN4Nodular hyperplasiaN5Follicular adenomaN6Nodular hyperplasia with focal lymphocytic thyroiditisN7Nodular hyperplasiaN8Follicular adenomaN9Nodular hyperplasiaN10Follicular adenomaN11Grave's thyroiditisT1Solid/FVPTCT2FVPTCT3PTC classic morphologyT4FVPTC-oxyphilT5FVPTCT6FVPTCT7PTC classic morphologyT8FVPTCT9PTC classic morphologyT10FVPTCT11PTC classic morphologyT12FVPTCT13PTC classic morphologyT14PTC classic morphologyList of the 11 benign and 14 malignant lesions that were used in this study.*FV* follicular variant; *PTC* papillary thyroid carcinoma

RNA isolation and characterization {#Sec4}
----------------------------------

Samples were ground in liquid nitrogen and homogenised in RLT buffer (Qiagen, UK). RNA was then extracted using the RNeasy Mini Kit with optional on-column RNase-free DNase digestion (Qiagen) according to the manufacturer's instructions. RNA quantity was determined using UV spectrophotometry. RNA quality was assessed using the RNA 6000 Nano LabChip® Kit in conjunction with the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).

Microarray analysis {#Sec5}
-------------------

Applied Biosystems Human Genome Survey Arrays were used to analyse the transcriptional profiles of thyroid RNA samples in this study. Digoxigenin-UTP-labelled cRNA was generated and linearly amplified from 5 μg of total RNA using Applied Biosystems Chemiluminescent RT-IVT Labelling Kit v 2.0 using manufacturer's protocol. 10 μg of labelled cRNA were hybridized to each pre-hybed microarray in a 1.5-ml volume at 55°C for 16 h. Array hybridization and chemiluminescence detection were performed using Applied Biosystems Chemiluminescence Detection Kit following manufacturer's protocol. Images were collected for each microarray using the 1700 analyser. Images were auto-gridded and the chemiluminescent signals were quantified, corrected for background and spot, and spatially normalized.

TaqMan® PCR validation {#Sec6}
----------------------

Sufficient RNA remained from 20 of the initial 25 samples for TaqMan® polymerase chain reaction (PCR) validation in a series of 50 targets. RNA was reverse transcribed using a High Capacity cDNA Archive Kit (Applied Biosystems, CA, USA). Primers and probes for TaqMan® PCR were obtained by using Applied Biosystems' pre-designed TaqMan® Gene Expression Assays. PCR was carried out using an ABI PRISM 7900 Sequence Detection System (Applied Biosystems). Analysis of relative gene expression data was performed using the ΔΔCT method \[[@CR23]\] with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control/reference assay.

Statistical analysis {#Sec7}
--------------------

Microarrays were analysed using Spotfire DecisionSite™ for Functional Genomics (Spotfire AB, Goteborg, Sweden) and R version 1.9.1, a free language and environment for statistical computing and graphics (R Development Core Team, 2004). Arrays were initially normalized, and genes were deemed undetectable and, therefore, excluded from final gene lists if they had a signal-to-noise ratio of less than three (S/N \< 3) in greater than 18 of the 25 arrays.

An ANOVA test was used to generate *p* values for statistical differences between groups. Their *p* values were then adjusted for multiple comparisons using the technique described by Benjamini and Yekutieli \[[@CR3]\]. Genes were deemed statistically different between groups if they had an adjusted *p* \< 0.05 and an average fold-change difference of greater than 2. Hierarchical clustering was performed based on the statistically different genes to determine whether samples grouped appropriately. Gene ontology analysis was performed using an online database known as the Panther classification system (<http://www.pantherdb.org>). Correlations between microarray and TaqMan® expression data were measured using the Pearson coefficient.

Results {#Sec8}
=======

Unsupervised clustering of all 25 samples demonstrated clustering into two major groups (data not shown) comprising the N group and the T group (see Table [1](#Tab1){ref-type="table"}). There was no tendency for FVPTC to cluster independently with classic morphology PTC, confirming the close relationship of these variants of PTC. To identify potential markers of malignancy, ANOVA with false discovery rate correction was used to compare the benign and malignant thyroid cohorts. A *p* value cut-off of \<0.05 and fold-change difference of ≥2 yielded 236 statistically significant probes. Of these, 172 corresponded to fully annotated probes and are listed in Table [2](#Tab2){ref-type="table"}. Table 2Genes differentially expressed in malignant vs benign thyroid tissueGene NameGene SymbolAdjusted *p* value1700 probe IDGenes up-regulated in malignant vs benign Active BCR-related geneABR0.014482154399 Adaptor-related protein complex 2, alpha 1 subunitAP2A10.0312115368 Apoptosis, caspase activation inhibitorAVEN0.030998203738 BCL2-associated X proteinBAX0.009782146510 BH3 interacting domain death agonistBID0.021424131216 Brain abundant, membrane attached signal protein 1BASP10.024214198318 Brain acyl-CoA hydrolaseBACH0.014566133876 Bromodomain adjacent to zinc finger domain, 1ABAZ1A0.03538209809 Calcium/calmodulin-dependent protein kinase ICAMK10.041887157712 Cathepsin SCTSS0.046544105790 CD44 antigen (homing function and Indian blood group system)CD440.044181133604 Chemokine (C-X-C motif) ligand 16CXCL160.043234199059 Chromosome 1 open reading frame 38C1orf380.049072202924 CLIP-170-related proteinCLIPR-590.023629102205 Docking protein 1, 62 kDa (downstream of tyrosine kinase 1)DOK10.041898204989 Epidermodysplasia verruciformis 1EVER10.003348175569 FXYD domain containing ion transport regulator 5FXYD50.01444154607 FXYD domain containing ion transport regulator 5FXYD50.023629112771 Galactose-4-epimerase, UDPGALE0.047363141143 Genethonin 1GENX-34140.016836124360 Hypothetical gene BC008967BC0089670.015683108526 Hypothetical protein FLJ10849FLJ108490.013822224983 Hypothetical protein FLJ22531FLJ225310.024391145918 Hypothetical protein MGC4607MGC46070.006507211836 Intercellular adhesion molecule 1 (CD54), human rhinovirus receptorICAM10.028746109070 Jun dimerization protein p21SNFTSNFT0.043301144215 Lectin, galactoside-binding, soluble, 3 (galectin 3)LGALS30.034491179836 Major vault proteinMVP0.0312212354 Matrix metalloproteinase 14 (membrane-inserted)MMP140.038682152076 Milk fat globule-EGF factor 8 proteinMFGE80.02392144588 Mst3 and SOK1-related kinaseMST40.042028112198 neuronal cell adhesion moleculeNRCAM0.011178106462 Phospholipase D3PLD30.034491143388 Promyelocytic leukemiaPML0.016018217558 Protein inhibitor of activated STAT protein PIASyPIASY0.00536153434 Protein tyrosine phosphatase, receptor type, EPTPRE0.048653221568 Rho GDP dissociation inhibitor (GDI) betaARHGDIB0.043853143589 S100 calcium binding protein A11 (calgizzarin)S100A110.019933145550 Similar to rat tricarboxylate carrier-like proteinBA108L7.20.025387179870 SP110 nuclear body proteinSP1100.0312113484 Stimulated by retinoic acid gene 6FLJ125410.043234193986 Syndecan 3 (N-syndecan)SDC30.048804143980 Tax interaction protein 1TIP-10.006673119665 TBC1 domain family, member 2TBC1D20.029907205982 Tenascin C (hexabrachion)TNC0.032355143831 Thymosin, beta 4, Y chromosomeTMSB4Y0.040937193911 Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)TIMP10.032306134692 Topoisomerase (DNA) II alpha 170 kDaTOP2A0.040937135302 Transforming growth factor, beta 1TGFB10.016836170749 Transgelin 2TAGLN20.031971172296 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptideYWHAH0.039009188379 v-yes-1 Yamaguchi sarcoma viral related oncogene homologLYN0.016175194134Genes down-regulated in malignant vs benign Aldehyde oxidase 1AOX10.003227106573 Ankyrin 2, neuronalANK20.035357155780 Aspartate beta-hydroxylaseASPH0.002064221656 Aspartate beta-hydroxylaseASPH0.019666114180 ATPase, Cu++ transporting, beta polypeptideATP7B0.044511198852 Brain-specific protein p25 alphap250.023629120622 Casein kinaseLOC1494200.022382149347 Cellular retinoic acid binding protein 1CRABP10.008315100295 Centromere protein JCENPJ0.0312164563 Ceroid-lipofuscinosis, neuronal 5CLN50.011021205999 Chloride channel KbCLCNKB0.040418176266 Chondroitin beta1,4 *N*-acetylgalactosaminyltransferaseChGn0.013148101140 Chromosome 11 open reading frame 8C11orf80.001977174025 Chromosome 11 open reading frame 8C11orf80.004148108279 Chromosome 21 open reading frame 4C21orf40.0042156895 Clusterin-like 1 (retinal)CLUL10.019631186062 Component of oligomeric golgi complex 3COG30.003664129212 Coxsackie virus and adenovirus receptorCXADR0.004648108284 Crystallin, alpha BCRYAB0.030418190274 Cytosolic sialic acid 9-*O*-acetylesterase homologCSE-C0.040993213856 Dicarbonyl/[l]{.smallcaps}-xylulose reductaseDCXR0.001977103350 DnaJ (Hsp40) homolog, subfamily B, member 4DNAJB40.043853103618 ERO1-like beta (*S. cerevisiae*)ERO1LB0.013962207998 Extracellular link domain containing 1XLKD10.039738195865 Family with sequence similarity 13, member A1FAM13A10.019631116936 Fatty acid binding protein 4, adipocyteFABP40.014832150137 Fc fragment of IgG binding proteinFCGBP0.001965118361 Fibroblast growth factor receptor 2FGFR20.0042110548 FLJ35740 proteinFLJ357400.020224101102 Friedreich ataxia region gene X123X1230.032602133505 Glutamate-ammonia ligase (glutamine synthase)GLUL0.014649175147 Glycine amidinotransferase ([l]{.smallcaps}-arginine/glycine amidinotransferase)GATM0.013962111904 Glycoprotein M6AGPM6A0.011739215326 Growth hormone receptorGHR0.017721190306 HLA complex group 4HCG40.025807191199 Hypothetical protein BC009561LOC1197100.003227211319 Hypothetical protein BC019238LOC1203790.013438201200 Hypothetical protein FLJ13204FLJ132040.003227145066 Hypothetical protein FLJ13842FLJ138420.016448208504 Hypothetical protein FLJ14054FLJ140540.049072202017 Hypothetical protein FLJ20154FLJ201540.014428143310 Hypothetical protein FLJ20513FLJ205130.019493154130 Hypothetical protein FLJ32110FLJ321100.015507229492 Hypothetical protein FLJ32343FLJ323430.012208116902 Hypothetical protein FLJ33516FLJ335160.03965224600 Hypothetical protein FLJ37549FLJ375490.001956218577 Hypothetical protein FLJ39378FLJ393780.005853163223 Hypothetical protein FLJ40021FLJ400210.023629174198 Hypothetical protein LOC134285LOC1342850.018694163671 Hypothetical protein MGC10946MGC109460.022382195982 Hypothetical protein MGC14425MGC144250.015445161569 Hypothetical protein MGC17299MGC172990.026062168452 Hypothetical protein MGC17943MGC179430.0042147296 Hypothetical protein MGC23980MGC239800.018694224619 Hypothetical protein MGC24047MGC240470.001956138122 Hypothetical protein MGC33607MGC336070.033547100645 Ionized calcium binding adapter molecule 2IBA20.0042179489 KIAA0390 gene productKIAA03900.014832119936 KIAA0703 gene productKIAA07030.032602146652 Lectin, mannose-binding, 1LMAN10.031092179632 Leiomodin 1 (smooth muscle)LMOD10.022352120404 Likely ortholog of rat SNF1/AMP-activated protein kinaseSNARK0.044605157942 LIM domain kinase 2LIMK20.002409151439 Low density lipoprotein-related protein 1B (deleted in tumors)LRP1B0.00536209464 Low density lipoprotein-related protein 2LRP20.040937114919 Matrilin 2MATN20.0042167316 Metallothionein 1A (functional)MT1A0.013822204773 Metallothionein 1A (functional)\|metallothionein 1E (functional)\|metallothionein 1K\| metallothionein 2AMT1A\|MT2A\|MT1E\|MT1K0.027037146368 Metallothionein 1A (functional)\|metallothionein 1E (functional)\|metallothionein 2A\| metallothionein 1KMT1A\|MT2A\|MT1K\|MT1E0.043841182305 Metallothionein 1A (functional)\|metallothionein 2A\|metallothionein 1K\| metallothionein 1E (functional)MT1A\|MT1K\|MT1E\|MT2A0.011739223856 Metallothionein 1B (functional)MT1B0.019631174119 Metallothionein 1F (functional)MT1F0.024726144569 Metallothionein 1GMT1G0.0192164525 Metallothionein 1GMT1G0.03965171539 Metallothionein 1JMT1J0.008315227956 Metallothionein 1XMT1X0.008335119685 Metallothionein 1XMT1X0.010748173072 Metallothionein IVMT40.007447223241 Methionine adenosyltransferase II, alphaMAT2A0.014428158350 Mitogen-activated protein kinase 4MAPK40.042306131252 Myc-induced nuclear antigen, 53 kDaMINA530.011959130284 NIMA (never in mitosis gene a)- related kinase 11NEK110.001965194628 OtospiralinLOC1506770.018694182360 PDZ/coiled-coil domain binding partner for the rho-family GTPase TC10PIST0.013822103651 Phospholipase A2 receptor 1, 180 kDaPLA2R10.004029134379 Phospholipase C-like 1PLCL10.022657206894 Phosphotidylinositol transfer protein, betaPITPNB0.014428122698 Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1PKHD1L10.0042199896 Polymerase (DNA directed) iotaPOLI0.003227167492 Potassium channel, subfamily K, member 9KCNK90.000849108648 Potassium channel-interacting protein 4KCNIP40.011447147058 Potassium inwardly-rectifying channel, subfamily J, member 13KCNJ130.008972124187 pp21 HomologLOC511860.004326127636 Pre-B cell leukemia transcription factor 4PBX40.030311199118 Protein kinase, cAMP-dependent, catalytic, betaPRKACB0.023863198878 Protein phosphatase 4, regulatory subunit 2\|hypothetical protein LOC151987PPP4R2\|LOC1519870.011338200919 RAB23, member RAS oncogene familyRAB230.000659122394 Ras association (RalGDS/AF-6) domain family 6RASSF60.048804119072 Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein)SGCD0.011178120415 Serum deprivation response (phosphatidylserine binding protein)SDPR0.011021156433 SH3 and multiple ankyrin repeat domains 2SHANK20.043996193906 Solute carrier family 26, member 7SLC26A70.0042225067 Solute carrier family 26, member 7SLC26A70.005853213530 Solute carrier family 5 (iodide transporter), member 8SLC5A80.031284231731 SPARC related modular calcium binding 2SMOC20.021505135930 Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan)SDC20.001258209676 Syntaxin 12STX120.01117199949 T-box 22TBX220.024297177517 Thioredoxin-like, 32 kDaTXNL0.001102192552 Thyroid stimulating hormone receptorTSHR0.02176108606 Tissue inhibitor of metalloproteinase 4TIMP40.023629184795 Trefoil factor 3 (intestinal)TFF30.004648114445 Trefoil factor 3 (intestinal)TFF30.014428100949 UDP-*N*-acetyl-alpha-[d]{.smallcaps}-galactosamine/polypeptide *N*-acetylgalactosaminyltransferase 9 (GalNAc-T9)GALNT90.031284161042 WEE1 homolog (*S. pombe*)WEE10.024101123533 WW domain containing oxidoreductaseWWOX0.012208224298 WW domain containing oxidoreductaseWWOX0.024101135080 Zinc finger protein 258ZNF2580.013962225961 Zinc finger protein 36, C3H type-like 2ZFP36L20.018837210469Two-tail ANOVA with *p* value correction yielded 173 probes (52 up-, 121 down-regulated in PTC) significantly different (*p* \< 0.05) between the malignant and benign thyroid tissues.

Supervised hierarchical clustering was performed on the 25 arrays based on the 236 statistically significant probes to determine whether the samples would segregate appropriately. The resulting heat map can be observed in Fig. [1](#Fig1){ref-type="fig"}. Benign lesions and tumours clustered together with the exception of one tumour sample that clustered with the benign group (T5). Fig. 1Hierarchical clustering of samples. This heat map shows the clustering of the 25 samples based on the 236 probes found to be differentially regulated in benign vs malignant thyroid tissue. Clustering was performed using the unweighted pair group method with arithmetic mean, with Euclidian distance as the similarity measure. Average value was used as the ordering function

A binomial statistics tool was used to compare classifications of multiple clusters of lists to a reference list (i.e. the complete human genome) to statistically determine over- or under-representation of Panther classification categories. Biological processes over-represented in the up-regulated PTC cohort included tumour suppressor, oncogenesis, DNA replication, cell cycle, and cell adhesion (*p* \< 0.0001). Genes involved in homeostasis and other homeostasis activities were highly over-represented in the down-regulated cohort (*p* \< 0.000001).

ANOVA tests were used to determine which genes were differentially regulated in the FVPTC cohort only. Fifteen genes were identified, including cluster of differentiation 14 (CD14), CD74, CTSC, CTSH, CTSS, DPP6, ETHE1, human leucocyte antigen A (HLA-A), HLA-DMA, HLA-DPB1, HLA-DQB1, HLA-DRA, osteoclast stimulating factor 1 (OSTF1), TDO2, and a previously uncharacterized gene (noname).

Microarray results were validated using a reverse transcription reaction followed by TaqMan® PCR for 50 gene targets. The ΔΔCT method \[[@CR23]\] was used to analyse relative gene expression data. GAPDH was used as an endogenous control, and T12 was chosen as an arbitrary calibrator sample. Gene expression profiles for TaqMan® PCR were plotted in conjunction with those for microarray results in Fig. [2](#Fig2){ref-type="fig"}. Pearson co-efficient was used to directly compare data from microarray analysis and TaqMan® RT-PCR. Table [3](#Tab3){ref-type="table"} depicts genes differentially expressed in both benign vs malignant and FVPTC vs classic morphology PTC. Fig. 2TaqMan® PCR validation of microarray experiments. Profile charts of gene expression levels comparing results obtained by microarray analysis (*n* = 25) to TaqMan® PCR analysis (*n* = 20) for six genes. Plots for those genes with multiple probes are also displayed where appropriateTable 3Correlation between TaqMan® and microarray dataGenePearson's *r* coefficienttwo-tailed *p*Genes differentially expressed in FVPTC vs classic PTCCD140.83\<0.0001CD74^a^0.87\<0.00010.740.0002CTSC0.530.0170CTSH0.710.0005CTSS0.620.0037DPP60.760.0001ETHE10.300.2008HLA-A0.77\<0.0001HLA-DMA0.750.0001HLA-DPB10.96\<0.0001HLA-DQB1^a^0.700.00060.630.0031HLA-DRA0.82\<0.0001NONAME−0.020.9323OSTF10.150.5171TDO20.680.0009Genes differentially expressed in benign vs malignantBAX0.200.3997CAMK10.170.4771CD440.570.0094CTSS0.620.0037CXADR0.360.1152FGFR20.84\<0.0001GALE0.540.0138ICAM10.620.0038LYN0.450.0483MAPK40.76\<0.0001MMP140.360.1175MT1F0.92\<0.0001MT1K^a^0.680.00110.690.00070.700.0006MT1X^a^0.88\<0.00010.88\<0.0001RAB230.700.0006S100A110.610.0041SDC20.340.1415SDC30.570.0087TFF3^a^0.97\<0.00010.96\<0.0001TGFB10.560.0098TIMP10.730.0003TIMP40.80\<0.0001TOP2A0.070.7769TSHR0.180.4440Gene expression profiles for TaqMan® PCR and microarray results were compared using the Pearson coefficient.^a^Genes have more than one probe ID on microarray

Discussion {#Sec9}
==========

The primary aim of this study was to generate an overview of molecular markers of malignancy in PTC with a view to identifying discriminators between common sub-types (classic PTC and FVPTC), using genome-wide expression microarray technology validated by TaqMan® RT-PCR. To this end, lesions that were well characterized histologically were selected.

The application of microarray analysis designed to identify transcripts strongly associated with each group of interest yielded a gene list of 173 genes that were differentially expressed between cohorts. Significant down-regulation of Coxsackie virus receptor was recorded in the malignant cohort of thyroid lesions. The Coxsackievirus B and adenovirus receptor (CAR) plays a dual role as a homotypic junctional adhesion protein and as a viral receptor. It is biologically plausible that altered expression may impact on the morphology peculiar to PTC given its association with cellular adhesion. CAR has been shown to be differentially expressed in various human adenocarcinomas, and differential expression may represent a new factor in thyroid tumourigenesisigenesis \[[@CR27]\].

Rab 23 expression was also down regulated in the malignant cohort. The Rab small G protein family is composed of approximately 40 members. Many of them are ubiquitous and are expressed and participate in transport processes, such as endocytosis and exocytosis \[[@CR26]\]. Other gene targets demonstrating significant down-regulation in the malignant group were syndecans 2 and 3. Syndecans are transmembrane proteoglycans expressed on adherent cells. Changes in syndecan expression have been postulated to influence cell adhesion, migration, and the structure of focal contacts and the cytoskeleton \[[@CR8]\].

The abundance of metallothionein genes in the cohort of genes down-regulated in PTC is interesting partly because of the sheer number of isoforms detected (Table [2](#Tab2){ref-type="table"}). There have been many studies showing increased metallothionein expression in a plethora of cancer types but few showing decreased expression \[[@CR4], [@CR7], [@CR33]\]. Although previous microarray experiments showed metallothionein genes to be down-regulated in thyroid tumours to a certain extent \[[@CR2], [@CR9], [@CR16]\], none have detected so many as the current study.

Apart from microarray experiments, there has been little reported in the literature regarding metallothioneins in thyroid cancer. An early report by Nartey et al. \[[@CR31]\] showed metallothioneins to be expressed actively in certain human thyroid neoplastic tissues but not in normal thyroid tissue, which would seem to contradict the current authors' findings. In contrast to this, a later immunohistochemical study showed an absence of metallothionein expression in 13 of 20 PTCs \[[@CR36]\]. Interestingly, in three of the seven positive PTCs, metallothionein positivity was restricted to areas of follicular differentiation. In one of the only recent studies, Huang et al. \[[@CR17]\] followed up their initial microarray experiment by showing that MT1G is down regulated in PTC via hypermethylation. The biological significance of low metallothionein expression in thyroid tumours is therefore still poorly understood; however, it is interesting to speculate that metallothioneins may have roles as tumour suppressors in thyroid carcinoma.

Many genes identified, such as *LGALS3* \[[@CR9], [@CR16], [@CR20]\], *LYN* \[[@CR46]\], *TFF3* \[[@CR2], [@CR9], [@CR16]\], *CRABP1* \[[@CR9], [@CR16]\], *BAX* \[[@CR2]\], *MAPK4* \[[@CR28]\], *CD44* \[[@CR16]\], *TIMP1* \[[@CR20]\], *FGFR2* \[[@CR9]\], and *S100A11* \[[@CR20], [@CR40]\], have been previously reported in both microarray and conventional experiments in thyroid cancer. The data generated in this study corroborates the importance of several biological processes in the progression of thyroid neoplasia. For example, S100A11 expression was up regulated in the PTC cohort compared with benign lesions, paralleling the increased protein expression of this gene target identified at the protein level using immunohistochemistry \[[@CR29]\]. S100A11 has also been suggested as a biomarker of malignancy in the context of colorectal carcinoma as long ago as 1995 \[[@CR41]\].

Correlation of highlighted features with the current state of knowledge of the molecular pathology of thyroid neoplasia goes some way towards providing an external validation of the data obtained from the AB1700 system. However, additional validation using TaqMan® RT-PCR was performed.

In general, microarray and TaqMan® data correlated well with approx. 80% of comparisons having *p* \< 0.05. Candidate genes were selected contingent on results identified as over-represented biological processes (oncogenesis, cell cycling, DNA replication, and homeostasis) using the Panther binomial statistics tool as opposed to the more traditional method of selecting the most highly disregulated genes. This may account for the poor correlation observed with certain genes. Some genes, such as TFF3 and FGFR2, had excellent correlation between microarray and TaqMan® results, whereas others, such as BAX and TSHR, showed poor correlation despite previous studies implicating them in thyroid cancer \[[@CR15], [@CR38]\]. Where there was discordance in the data, it could be accounted for by differences in the sequences targeted by the TaqMan® target sequences and the microarray probe. In those cases, the array and pre-designed TaqMan assays interrogated different exons or alternative splice variants. This finding highlights the importance of matching the targets to be validated from microarray data sets.

Analysis of differentially expressed transcripts in the FVPTC revealed many transcripts showing similar expression level patterns in both FVPTC and classic morphology PTC. Examples of these transcripts are included in Table [2](#Tab2){ref-type="table"}. In addition, somewhat surprisingly, unsupervised clustering of all samples showed no tendency for FVPTC to cluster independently of classic morphology PTC, emphasizing the very close relationship of these PTC variants (data not shown). However, analysis of differentially expressed genes in FVPTC exclusive of those identified in classic morphology PTC revealed 15 genes exhibiting differential expression in FVPTC compared with benign lesions and conditions outwith of classic morphology PTC. These genes displayed a narrow gamut of function represented by the transcripts involved (Table [3](#Tab3){ref-type="table"}). TaqMan® RT-PCR was performed for all of these targets to confirm the array findings and correlation with the array data was strong (see Table [3](#Tab3){ref-type="table"}).

Aberrant expression of two major groups of transcripts was noted in FVPTC. Relatively increased expression of class 1 major histocompatibility complex (MHC) genes (HLA-A) and aberrant expression of class 2 MHC genes (HLA-DMA, HLA-DPB-1, HLA-DQB-1, HLA DRA) and associated genes (e.g. CD74 represents the invariant membrane bound moiety of class II HLA molecules and regulates the biology and functions of MHC class II molecules and CD14 is a surface marker of monocytes/macrophages) were the most significant findings. Additionally, relatively up-regulated expression of members of the cathepsin family (cathepsin C, cathepsin H, cathepsin S, and TDO2) was striking in the FVPTC group. HLA expression is generally associated with immune functions such as T cell interaction and antigen presentation. The presence of prominent HLA transcript expression, especially among class 2 in FVPTC, is intriguing. One potential cause of this was that tumour-infiltrating leucocytes were responsible for this finding. However, haematoxylin--eosin (H&E)-stained slides of each case were reviewed to specifically identify the degree of tumour infiltration by leucocytes. Although a mild lymphocytic infiltrate was noted in some cases, there was no apparent over representation of lymphocytes in the follicular variant compared to benign lesions and classic morphology PTC. This raises the clear possibility that the findings represent aberrant increased expression of class 2 HLA transcripts by the epithelium of FVPTC. This is an unexpected finding, as over-expression of MHC class 2 molecules would be expected to increase tumour immunogenicity. A similar aberrant expression of HLA transcripts has been recently described in ovarian neoplasms \[[@CR34]\]. Rangel et al. \[[@CR34]\] concluded over-expression of HLA-DRA might represent a novel biomarker for malignancy, and this also seems biologically plausible in the FVPTC setting. A recent paper has also described HLA-DRA expression in ret/PTC-activated papillary thyroid carcinoma but not in surrounding normal thyroid follicles \[[@CR19]\]. Yu et al. \[[@CR47]\] showed discordant expression of (CD74Ii) and HLA-DR in Hashimoto thyroiditis, an autoimmune condition associated with increased incidence of PTC and sharing molecular features such as ret/PTC expression \[[@CR18], [@CR37]\]. Hwang et al. \[[@CR19]\] have drawn attention to aberrant expression of HLA-DRA in ret/PTC-activated PTC. Expression of HLA-DRA may in some way explain the propensity for PTC to metastasize to lymph nodes and often apparently reside there without markedly worsening prognosis.

Cathepsins C (dipeptidyl-peptidase I), H, and S showed up-regulation in FVPTC compared to benign lesions. Cathepsins are a family of proteases that play an important role in protein degradation. They are key players in the proliferative, invasive, and metastatic potential of malignant tumour cells. Their expression in the relatively biologically indolent FVPTC is intriguing, and it remains possible that cathepsins have cellular roles outside of those involved in invasion and dissemination of tumour cells as indeed has been suggested by others \[[@CR43]\]. For example, cathepsin L has recently been shown to play a role in nuclear transcriptional activation, and cathepsins are now recognized to play a role in MHC class II antigen presentation \[[@CR44]\]. OSTF1 has no defined role in carcinogenesis, although outside of its role in ossification, it is also known to have roles in signal transduction and protein binding, which may be relevant to carcinogenesis and, particularly, FVPTC. A recent paper highlights the role of bone mineralization proteins including osteopontin and osteoclast stimulating factors as potential biomarkers of malignant tumours in general \[[@CR1]\]. Indeed, in addition to elevated OSTF1 expression, increased expression of osteopontin was seen in PTC (data not shown); however, in our data, osteopontin does not appear to be specifically up-regulated in FVPTC, and this finding has also been noted by other researchers \[[@CR14]\]. In any case, osteopontin is known to be a downstream effector of ret/PTC \[[@CR5]\] and mutated BRAF \[[@CR14]\], where it acts in association with CD44, another transcript showing increased expression in both classic morphology PTC and FVPTC.

A particular focus of this study was to compare transcriptome profiles for PTCs with classic morphology and FVPTC given the propensity for FVPTC lesions to prove problematic from a diagnostic perspective. Although the study confirms the close relationship between the two most common variants of PTC, a narrow portfolio of genes and, in particular, gene functions was elucidated in the FVPTC cohort. The targets identified are easily amenable to analysis by more established techniques such as TaqMan® RT-PCR, with associated potential as additional markers for application in the FNAC setting. Clearly, the potential biomarkers identified in this study will require prospective evaluation in the context of real clinical diagnostic situations in the future to consolidate their merit as adjunctive tests in the diagnostic setting and to validate their altered expression states in the pathobiology of PTC development.
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